Anika Therapeutics Reports 4Q18 Orthobiologic Revenue of $23.8MM, -5.3% vs. 4Q17

Anika Therapeutics reported 4Q18 orthobiologic revenue of $23.8MM, -5.3% vs. 4Q17, with 2018 full year orthobiologic revenue of $93.6MM, -0.2% vs. 2017. The downward trend is expected to continue in 2019, with company revenue guidance given in the range of -3% to -6% below 2018. Leadership deemed 2018 a “snapshot of a company undergoing a...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us